His research focusses on ovarian cancer, specifically developing improved therapies through improved understanding of disease biology. He leads the BriTROC translational research collaborative and his lab investigates copy number alterations in ovarian high grade serous carcinoma (HGSC) as a possible prognostic and predictive biomarker. His group has also recently developed novel transplantable murine models of HGSC using CRISPR/Cas9 gene editing technology to allow investigation of novel therapies in an immunocompetent model. These transplantable cells are freely available to researchers.